Treatment and biomarker testing patterns,treatment outcomes in a/m NSCLC with and without actionable genomic alterations

Trial Identifier: D133FR00204
Sponsor: AstraZeneca
Start Date: March 2024
Primary Completion Date: June 2026
Study Completion Date: June 2026
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Arkhangelsk, Russia
Russia Barnaul, Russia
Russia Ekaterinburg, Russia
Russia Irkutsk, Russia
Russia Kemerovo, Russia
Russia Kostroma, Russia
Russia Krasnoyarsk, Russia
Russia Novokuznetsk, Russia
Russia Novosibirsk, Russia
Russia Obninsk, Russia
Russia Perm, Russia
Russia Saint-Petersburg, Russia
Russia Ufa, Russia
Russia Vladivostok, Russia
Russia Yaroslavl, Russia